Assessing MGTA-145 in Mobilizing Stem Cells for Use in ASTC for Hematological Malignancies | Aplastic Anemia & MDS International Foundation Return to top.
Assessing MGTA-145 in Mobilizing Stem Cells for Use in ASTC for Hematological Malignancies

Clinical Trial: NCT04762875

For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

This is a Phase II, open-label, multicenter, prospective study of MGTA-145 + plerixafor mobilized HLA-matched sibling and matched unrelated donor allografts for myeloablative hematopoietic stem cell transplantation (HSCT) in recipients with hematological malignancies. Donors will undergo 1 or 2 days of mobilization and apheresis.

Status: 
Recruiting
Study Date: 
Mon, 02/22/2021 ( ) to Tue, 08/01/2023 ( )
Bone Marrow Disease(s): 
  • acute myeloid leukemia (AML)
  • aplastic anemia
  • graft versus host disease (GVHD)
  • myelodysplastic syndromes (MDS)
Intervention: 
Experimental: Single dose MGTA-145 plus plerixafor followed by apheresis MGTA-145 in combination with plerixafor followed by apheresis on one or two consecutive days Biological: MGTA-145 0.015 mg/kg dose intravenously Biological: Plerixafor 240 µg/kg subcutaneously Other Name: Mozobil
Share with addtoany.com.